This month’s issue of American Journal of Hematology/Oncology (AJHO), a peer-reviewed resource for education and the official journal of Physicians’ Education Resource®, LLC, features four peer-reviewed articles on recent advances that could be vital to the future of hematology and oncology treatment.
Our first story focuses on promising prostate cancer research indicating that degarelix may be a viable therapeutic option in the intermittent setting for maintaining PSA suppression, with the therapy found to be a suitable treatment option for men being considered for intermittent androgen ablation.
Metastatic breast cancer is the topic of our next article, which reviews inhibitors for Aurora A kinase signaling. Encouraging trials with alisertib have shown early signals of activity, especially among patients whose tumors are HR+ and HER2-positive.
Next, we look at recent progress in the treatment of transplant-eligible multiple myeloma. While chemotherapy with autologous stem cell transplant has been the mainstay of treatment since the mid-90s, a number of new therapeutic approaches, such as posttransplant consolidation therapy and maintenance therapy, have gained attention as potential treatment strategies.
The American Society of Hematology and the American Society of Clinical Oncology have developed recommendations for “Choosing Wisely,” a national initiative to optimize safety and efficiency in healthcare by encouraging evidence-based application of medical investigations and interventions. Our fourth article evaluates these recommendations, highlighting their rationale and anticipated benefits.
This month’s CME article is a discussion with George D. Demetri, MD, of the Dana-Farber Cancer Institute in Boston, on the evolving options currently available for managing soft tissue sarcomas.
Thank you for your support of AJHO in 2015. We look forward to serving you in the new year. Your comments and suggestions are always welcome, and we also invite you to submit original articles and commentaries.
I hope you have a happy, safe, and enjoyable holiday season!
Michael J. Hennessy, Sr
Chairman and Chief Executive Officer